source
- Boehringer's obesity injection shows 17% weight loss after 18 months, comparable to Wegovy but below ZepboundBoehringer Ingelheim, together with Zealand, released data from a late‑stage study of its experimental obesity injection. The trial followed patients for roughly a year and a half. Participants on…
- AI-driven admin tech continues to dominate health-tech funding landscapeThe article notes that administrative technology remains the leading segment within health‑tech investment. Startups that apply artificial intelligence to automate routine tasks such as patient fol…